Have any questions? 706-721-6582 or cts@augusta.edu
- (ADCT-402-103) A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Clinical Trial
(ADCT-402-103) A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
This research study is for patients with diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) that has gotten worse or come back after treatment. This research study is designed to test the safety and antitumor activity of the investigational drug ADCT-402 (Locastuximab Tesirine) in combination with ibrutinib in treating DLBCL or MCL.
- Lymphatic System
- Diffuse Large B-cell Lymphoma
- DLBCL
- Ibrutinib
- Loncastuximab Tesirine
- Mantle Cell Lymphoma (MCL)
Eligibility Criteria
- Inclusion criteria: Male and female patients aged 18 years or older Patients with measureable DLBCL or MCL disease that has not responded or returned following treatment with standard therapy Exclusion criteria: Previous therapy with ibrutinib or loncastuximab tesirine Bone marrow transplant within 60 days prior to start of study Active graft-versus-host disease or active autoimmune disease Full inclusion/exclusion criteria may be found on ClinicalTrials.gov, or by contacting our clinical trials office.
RESEARCH. INNOVATION. DISCOVERY.